STK11 and neoplasm: Tumor cells evade immune recognition through antigen presentation defects (e.g., HLA-I loss) [12], oncogenic pathway activation (e.g., STK11/LKB1 mutations driving metabolic reprogramming) [13], and epigenetic silencing of tumor antigens [14].